[1] Yu C, Gong X, Yang Q, et al. The serum IL‐23 level predicts the response to pegylated interferon therapy in patients with chronic hepatitis B. Liver Int, 2015, 35: 1549-1556.
[2] Deng YQ, Zhao H, Ma AL, et al. Selected cytokines serve as potential biomarkers for predicting liver inflammation and fibrosis in chronic hepatitis B patients with normal to mildly elevated aminotransferases. Medicine, 2015, 94:e2003.
[3] Li J, Wang FP, She WM, et al. Enhanced high‐mobility group box 1 (HMGB1) modulates regulatory T cells (Treg)/T helper 17 (Th17) balance via toll-like receptor (TLR)-4-interleukin (IL)-6 pathway in patients with chronic hepatitis B. J Viral Hepat, 2014, 21: 129-140.
[4] López-Serrano P, de la Fuente Briongos E, Alonso EC, et al. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: When and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol, 2015, 7: 539-547.
[5] 中华医学会肝病学分会,中华医学会感染病学分会. 慢性乙型肝炎防治指南(2010年版). 中国病毒病杂志, 2011, 3:9-23.
[6] 中华医学会感染病学分会肝衰竭与人工肝学组,中华医学会肝病学分会重型肝病与人工肝学组. 肝衰竭诊治指南(2012年版). 中华移植杂志(电子版), 2013, 7:210-216.
[7] Sertorio M, Hou X, Carmo RF, et al. IL-22 and IL-22 binding protein (IL-22BP) regulate fibrosis and cirrhosis in hepatitis C virus and schistosome infections. Hepatology, 2015, 61: 1321-1331.
[8] 郑建铭, 鲍素霞, 李宁,等. 白细胞介素-23在慢性乙型肝炎-慢加急性(亚急性)肝功能衰竭患者血清和树突状细胞中的表达及其与预后的关系. 中华传染病杂志, 2017, 35:74-78.
[9] Ming D, Yu X, Guo R, et al. Elevated TGF-β1/IL-31 Pathway Is Associated with the Disease Severity of Hepatitis B Virus–Related Liver Cirrhosis. Viral Immunol, 2015, 28: 209-216.
[10] Ju H, Liu H, Tian ZB, et al. Association of polymorphisms in key Th-17 immune response genes with HBeAg-positive chronic hepatitis B susceptibility and response to PEG-IFNa-2α. Virology, 2017, 509: 35-41. |
